Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

por Cohen, Jordana B, Hanff, Thomas C, William, Preethi, Sweitzer, Nancy, Rosado-Santander, Nelson R, Medina, Carola, Rodriguez-Mori, Juan E, Renna, Nicolás, Chang, Tara I, Corrales-Medina, Vicente, Andrade-Villanueva, Jaime F, Barbagelata, Alejandro, Cristodulo-Cortez, Roberto, Díaz-Cucho, Omar A, Spaak, Jonas, Alfonso, Carlos E, Valdivia-Vega, Renzo, Villavicencio-Carranza, Mirko, Ayala-García, Ricardo J, Castro-Callirgos, Carlos A, González-Hernández, Luz A, Bernales-Salas, Eduardo F, Coacalla-Guerra, Johanna C, Salinas-Herrera, Cynthia D, Nicolosi, Liliana, Basconcel, Mauro, Byrd, James B, Sharkoski, Tiffany, Bendezú-Huasasquiche, Luis E, Chittams, Jesse, Edmonston, Daniel L, Vasquez, Charles R, Chirinos, Julio A
Publicado 2021